Hospira, a Pfizer company and provider of infusion technologies, announced the CE mark approval for a new intravenous (I.V.) connector, the Nuitiv Clear Needle-free Connector. Nuitiv will be launched globally, with immediate availability in Latin America, followed by Europe in early 2016.
“The development of the Nuitiv technology reinforces Hospira’s leadership in medical device innovation,” said Julie Sawyer Montgomery, vice president, Device Global Marketing and International Sales, Hospira. “Nuitiv was designed to support the reduction of catheter-related bloodstream infections (CRBSI) — a critical safety issue for patients and healthcare providers.”
Catheter-related bloodstream infections are the most common cause of healthcare-associated infection to the bloodstream, and I.V. needle-free connectors were designed to help decrease healthcare-associated CRBSI risk.1, 2 Hospira is launching the Nuitiv Clear Needle-free Connector as a reliable solution to support safer delivery of I.V. medication. The Nuitiv Clear Needle-free Connector is a neutral displacement I.V. connector that seamlessly integrates with infusion therapy protocols to reduce the risk of infection in both patients and health workers. With needle-free I.V. connectors used in nearly all I.V. administrations of patient medication, these devices represent a critical component of the $1.9 billion global I.V. consumables market.
The Nuitiv connector’s clear housing helps clinicians have a better view of the patient’s fluid pathway and helps ensure the connector is free of particulate — which can help prevent occlusions in the fluid pathway and infections. The connector has a smooth surface for disinfection, facilitating cleaning and compliance with best practices for maintaining aseptic technique and contamination prevention. The product’s clear housing and smooth top surface are key features that support healthcare providers in optimizing infection reduction strategies. Through this global launch, Hospira will continue to impact safe-medication delivery in a range of healthcare environments.
Hospira
www.pfizer.com
